Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) investors that a lawsuit was filed on behalf of investors that purchased Chemours securities between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”).

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

The lawsuit claims that during the Class Period, the Defendants deceived investors by falsely suggesting that: (1) they could secure FDA approval for lovo-cel without any severe warnings for blood cancers; (2) they would receive a priority review voucher from the FDA, which they could then sell to enhance their financial standing ahead of the lovo-cel launch; (3) consequently, the Company greatly exaggerated Lyfgenia's clinical and commercial potential; and (4) therefore, the Defendants' optimistic statements about the Company's business, operations, and future were substantially misleading and/or lacked a reasonable basis at all times concerned.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising